• 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:1130.
  • 2
    Grufferman S, Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev 1984; 6:76106.
  • 3
    Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:37653771.
  • 4
    Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13:7983.
  • 5
    Yahalom J. Changing role and decreasing size: Current trends in radiotherapy for Hodgkin's disease. Current Onc Reports 2002; 4:415423.
  • 6
    Specht L, Yahalom J, Illedge T, et al. Modern radiation therapy for hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2013; doi: 10.1016/j.ijrobp.2013.05.005
  • 7
    Mauch PM, Weinstein H, Botnick L, et al. An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer 1983; 51:925932.
  • 8
    Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.
  • 9
    Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:12081215.
  • 10
    Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma: Maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 2007; 17:230242.
  • 11
    Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10:16021608.
  • 12
    Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993; 11:100108.
  • 13
    Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience. J Clin Oncol 1994; 12:21602166.
  • 14
    Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 1991; 9:15911598.
  • 15
    Pearce MS, Parker L, Windebank KP, et al. Cancer in adolescents and young adults aged 15–24 years: A report from the North of England young person's malignant disease registry, UK. Pediatr Blood Cancer 2005; 45:687693.
  • 16
    Krasin MJ, Rai SN, Kun LE, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: Local disease control with combined-modality ttherapy. J Clin Oncol 2005; 23:84068413.
  • 17
    Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose or radiation in Hodgkin's disease: An analysis of clinical and treatment factors affecting in-field disease control. Int J Rad Biol Phys 1999; 44:551561.
  • 18
    Foltz LM, Song KW, Connors JM. Hodgkin's lymphoma in adolescents. J Clin Oncol 2006; 24:25202526.
  • 19
    Eichenauer DA, Bredenfeld H, Haverkamp H, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: A report from the German Hodgkin study group. J Clin Oncol 2009; 27:60796085.
  • 20
    Muller J, Illes A, Molnar Z, et al. Adolescent Hodgkin lymphoma: Are treatment results more favorable with pediatric than with adult reigmens? J Pediatr Hematol Oncol 2011; 33:e60e63.
  • 21
    Evans WC, Gilmore D, English J. The role of PET and PET/CT in managing the care of lymphoma patients. J Nucl Med Technol 2001; 39:190194.